Jasper Dingemanse

ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 44

Top Venues

Clinical and translational science

British journal of clinical pharmacology

Drugs in R&D

Journal of pharmacokinetics and pharmacodynamics

Idorsia Pharmaceuticals Ltd.

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Idorsia Pharmaceuticals Ltd.

Switzerland

VP, Head Clinical Pharmacology :: Clinical Pharmacology

Publications

Janneke M Brussee, Patricia N Sidharta, Jasper Dingemanse, Andreas Krause
Population pharmacokinetics of the dual endothelin receptor antagonist aprocitentan in subjects with or without essential or resistant hypertension. Journal of pharmacokinetics and pharmacodynamics 51 (3) (2024)
Ingrid W Koopmans, Daphne Geerse, Lara de Ridder, Melvyn Roerdink, Maria Joanna Juachon, Clemens Muehlan, Jasper Dingemanse, Joop M A Van Gerven, Geert Jan Groeneveld, Rob G J A Zuiker
The interactive walkway provides fit-for-purpose fall-risk biomarkers in the elderly: Comparison of zolpidem and suvorexant. Clinical and translational science 17 (7) (2024)
Christine Huynh, Jasper Dingemanse, Henriette E Meyer Zu Schwabedissen, Marlene Fonseca, Patricia N Sidharta
The effect of itraconazole, a strong CYP3A4 inhibitor, on the pharmacokinetics of the first-in-class ACKR3/CXCR7 antagonist, ACT-1004-1239. Clinical and translational science 17 (7) (2024)
Isabelle Zenklusen, Jasper Dingemanse, Christian Reh, Martine Géhin, Priska Kaufmann
Effect of Daridorexant on the Pharmacokinetics of Midazolam, and on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects. Drugs in R&D (2024)
Isabelle Zenklusen, Jasper Dingemanse, Christian Reh, Martine Géhin, Priska Kaufmann
Effect of Daridorexant on the Pharmacokinetics of Midazolam, and on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects. Drugs in R&D 24 (1) (2024)
Christine Huynh, Jasper Dingemanse, Henriette E Meyer Zu Schwabedissen, Marlene Fonseca, Patricia N Sidharta
The effect of itraconazole, a strong CYP3A4 inhibitor, on the pharmacokinetics of the first-in-class ACKR3/CXCR7 antagonist, ACT-1004-1239. Clinical and translational science 17 (7) (2024)
Ingrid W Koopmans, Daphne Geerse, Lara de Ridder, Melvyn Roerdink, Maria Joanna Juachon, Clemens Muehlan, Jasper Dingemanse, Joop M A Van Gerven, Geert Jan Groeneveld, Rob G J A Zuiker
The interactive walkway provides fit-for-purpose fall-risk biomarkers in the elderly: Comparison of zolpidem and suvorexant. Clinical and translational science 17 (7) (2024)
Christine Huynh, Jasper Dingemanse, Henriette E Meyer Zu Schwabedissen, Marlene Fonseca, Patricia N Sidharta
The effect of itraconazole, a strong CYP3A4 inhibitor, on the pharmacokinetics of the first-in-class ACKR3/CXCR7 antagonist, ACT-1004-1239. Clinical and translational science 17 (7) (2024)
Janneke M Brussee, Patricia N Sidharta, Jasper Dingemanse, Andreas Krause
Population pharmacokinetics of the dual endothelin receptor antagonist aprocitentan in subjects with or without essential or resistant hypertension. Journal of pharmacokinetics and pharmacodynamics 51 (3) (2024)
Isabelle Zenklusen, Jasper Dingemanse, Christian Reh, Martine Géhin, Priska Kaufmann
Effect of Daridorexant on the Pharmacokinetics of Midazolam, and on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects. Drugs in R&D 24 (1) (2024)
Isabelle Zenklusen, Jasper Dingemanse, Christian Reh, Martine Géhin, Priska Kaufmann
Effect of Daridorexant on the Pharmacokinetics of Midazolam, and on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects. Drugs in R&D 24 (1) (2024)
Massimo Magliocca, Benjamin Berger, Vincent Lemoine, Priska Kaufmann, Jasper Dingemanse
Value of Assessing 1-Hydroxymidazolam in Drug-Drug Interaction Studies with Midazolam as a Substrate of Cytochrome P450 3A. Journal of clinical pharmacology (2024)
Massimo Magliocca, Benjamin Berger, Vincent Lemoine, Priska Kaufmann, Jasper Dingemanse
Value of Assessing 1-Hydroxymidazolam in Drug-Drug Interaction Studies with Midazolam as a Substrate of Cytochrome P450 3A. Journal of clinical pharmacology 64 (9) (2024)
Ingrid W Koopmans, Daphne Geerse, Lara de Ridder, Melvyn Roerdink, Maria Joanna Juachon, Clemens Muehlan, Jasper Dingemanse, Joop M A Van Gerven, Geert Jan Groeneveld, Rob G J A Zuiker
The interactive walkway provides fit-for-purpose fall-risk biomarkers in the elderly: Comparison of zolpidem and suvorexant. Clinical and translational science 17 (7) (2024)
Janneke M Brussee, Patricia N Sidharta, Jasper Dingemanse, Andreas Krause
Population pharmacokinetics of the dual endothelin receptor antagonist aprocitentan in subjects with or without essential or resistant hypertension. Journal of pharmacokinetics and pharmacodynamics (2024)
Isabelle Zenklusen, Jasper Dingemanse, Christian Reh, Martine Géhin, Priska Kaufmann
Effect of Daridorexant on the Pharmacokinetics of Midazolam, and on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects. Drugs in R&D 24 (1) (2024)
Clemens Muehlan, Catherine Roch, Cedric Vaillant, Jasper Dingemanse
The orexin story and orexin receptor antagonists for the treatment of insomnia. Journal of sleep research (2023)
Clemens Muehlan, Catherine Roch, Cedric Vaillant, Jasper Dingemanse
The orexin story and orexin receptor antagonists for the treatment of insomnia. Journal of sleep research (2023)
Marion Anliker-Ort, Jasper Dingemanse, Luboš Janů, Priska Kaufmann
Effect of Daridorexant on the Pharmacokinetics of P-Glycoprotein Substrate Dabigatran Etexilate and Breast Cancer Resistance Protein Substrate Rosuvastatin in Healthy Subjects. Clinical drug investigation (2023)
Benjamin Berger, Priska Kaufmann, Matthias Berse, Alexander Treiber, Nathalie Grignaschi, Jasper Dingemanse
Effect of nivasorexant (ACT-539313), a selective orexin-1-receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in healthy subjects. Pharmacology research & perspectives 11 (5) (2023)
Marie-Laure Boof, Martine Géhin, Christine Voors-Pette, Chih-Hsuan Hsin, Virginie Sippel, Daniel S Strasser, Jasper Dingemanse
Pharmacokinetics, pharmacodynamics, and safety of the novel CXCR3 antagonist ACT-777991: Results from the first-in-human study in healthy adults. British journal of clinical pharmacology (2023)
Marion Anliker-Ort, Chih-Hsuan Hsin, Andreas Krause, Marc Pfister, John van den Anker, Jasper Dingemanse, Priska Kaufmann
Modeling time-delayed concentration-QT effects with ACT-1014-6470, a novel oral complement factor 5a receptor 1 (C5a 1 receptor) antagonist. Pharmacology research & perspectives 11 (4) (2023)
Clemens Muehlan, Catherine Roch, Cedric Vaillant, Jasper Dingemanse
The orexin story and orexin receptor antagonists for the treatment of insomnia. Journal of sleep research (2023)
Marion Anliker-Ort, Jasper Dingemanse, Stephane Delahaye, Luboš Janů, John van den Anker, Benjamin Berger, Priska Kaufmann
Evaluation of the cytochrome P450 2C19 and 3A4 inhibition potential of the complement factor 5a receptor antagonist ACT-1014-6470 in vitro and in vivo. Clinical and translational science (2023)
Uta Schilling, Chih-Hsuan Hsin, Stephane Delahaye, Andreas Krause, Hauke Wuelfrath, Atef Halabi, Jasper Dingemanse
Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of the P2Y12 receptor antagonist selatogrel. Clinical and translational science 15 (8) (2022)
Marion Anliker-Ort, Jasper Dingemanse, Chih-Hsuan Hsin, Muriel Richard, Eva Huehn, Giancarlo Sabattini, Jeroen van de Wetering, Rüdiger Kornberger, John van den Anker, Priska Kaufmann
First-in-human study with ACT-1014-6470, a novel oral complement factor 5a receptor 1 (C5aR1) antagonist, supported by pharmacokinetic predictions from animals to patients. Basic & clinical pharmacology & toxicology 131 (2) (2022)
Marion Anliker-Ort, Jasper Dingemanse, Hervé Farine, Peter M A Groenen, Rüdiger Kornberger, John van den Anker, Priska Kaufmann
Multiple-ascending doses of ACT-1014-6470, an oral complement factor 5a receptor 1 (C5a 1 receptor) antagonist: Tolerability, pharmacokinetics and target engagement. British journal of clinical pharmacology (2022)
Andreas Krause, Dominik Lott, Janneke M Brussee, Clemens Muehlan, Jasper Dingemanse
Population pharmacokinetic modeling of daridorexant, a novel dual orexin receptor antagonist. CPT: pharmacometrics & systems pharmacology (2022)
Marie-Laure Boof, Jasper Dingemanse, Katharina Lederer, Ingo Fietze, Mike Ufer
Effect of the new dual orexin receptor antagonist daridorexant on nighttime respiratory function and sleep in patients with mild and moderate obstructive sleep apnea. Sleep 44 (6) (2021)
Benjamin Berger, Jasper Dingemanse, Giancarlo Sabattini, Stéphane Delahaye, Urs Duthaler, Clemens Muehlan, Stephan Krähenbühl
Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor Antagonist. Clinical pharmacokinetics 60 (10) (2021)
Andrea Henrich, Pierre-Eric Juif, Jasper Dingemanse, Andreas Krause
PK/PD modeling of a clazosentan thorough QT study with hysteresis in concentration-QT and RR-QT. Journal of pharmacokinetics and pharmacodynamics 48 (2) (2021)
Martine Géhin, Jolanta Wierdak, Giancarlo Sabattini, Patricia N Sidharta, Jasper Dingemanse
Effect of gastric pH and of a moderate CYP3A4 inducer on the pharmacokinetics of daridorexant, a dual orexin receptor antagonist. British journal of clinical pharmacology (2021)
Benjamin Berger, Clemens Muehlan, Gernot Klein, Jasper Dingemanse
Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment. Clinical and translational science 14 (6) (2021)
Uta Schilling, Jasper Dingemanse, Michael Dobrow, Martine Baumann, Markus A Riederer, Pierre-Eric Juif, Mike Ufer
Insights from In Vitro and Clinical Data to Guide Transition from the Novel P2Y12 Antagonist Selatogrel to Clopidogrel, Prasugrel, and Ticagrelor. Thrombosis and haemostasis 121 (6) (2021)
Uta Schilling, Andrea Henrich, Clemens Muehlan, Andreas Krause, Jasper Dingemanse, Mike Ufer
Impact of Daridorexant, a Dual Orexin Receptor Antagonist, on Cardiac Repolarization Following Bedtime Dosing: Results from a Thorough QT Study Using Concentration-QT Analysis. Clinical drug investigation 41 (8) (2021)
Muriel Richard, Priska Kaufmann, Marion Anliker-Ort, Rüdiger Kornberger, Jasper Dingemanse
Multiple-Ascending Dose Study in Healthy Subjects to Assess the Pharmacokinetics, Tolerability, and CYP3A4 Interaction Potential of the T-Type Calcium Channel Blocker ACT-709478, A Potential New Antiepileptic Drug. CNS drugs 34 (3) (2021)
Marie-Laure Boof, Jasper Dingemanse, Mareile Brunke, Albert Esselmann, Peter Heymer, Olaf Kestermann, Katharina Lederer, Ingo Fietze, Mike Ufer
Effect of the novel dual orexin receptor antagonist daridorexant on night-time respiratory function and sleep in patients with moderate chronic obstructive pulmonary disease. Journal of sleep research 30 (4) (2021)
Mike Ufer, Debra Kelsh, Kerri A Schoedel, Jasper Dingemanse
Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem. Sleep (2021)
Dominik Lott, Pierre-Eric Juif, Jasper Dingemanse, Andreas Krause
Modelling pharmacokinetics and pharmacodynamics of the selective S1P1 receptor modulator cenerimod in healthy subjects and systemic lupus erythematosus patients. British journal of clinical pharmacology 86 (4) (2020)
Priska Kaufmann, Marion Ort, Georg Golor, Rüdiger Kornberger, Jasper Dingemanse
First-in-human study with ACT-539313, a novel selective orexin-1 receptor antagonist. British journal of clinical pharmacology 86 (7) (2020)
Benjamin Berger, Sander Brooks, Rob G J A Zuiker, Muriel Richard, Clemens Muehlan, Jasper Dingemanse
Pharmacological Interactions between the Dual Orexin Receptor Antagonist Daridorexant and Ethanol in a Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Four-Way Crossover Phase I Study in Healthy Subjects. CNS drugs 34 (12) (2020)
Benjamin Berger, Priska Kaufmann, Annelize Koch, Jasper Dingemanse
Impact of the Selective Orexin-1 Receptor Antagonist ACT-539313 on the Pharmacokinetics of the CYP3A Probe Drug Midazolam in Healthy Male Subjects. Journal of clinical pharmacology 60 (7) (2020)
Isabelle Zenklusen, Clemens Muehlan, Ivan Ulc, Jiří Liška, Jasper Dingemanse
The dual orexin receptor antagonist daridorexant does not affect the pharmacokinetics of the BCRP substrate rosuvastatin. Clinical and experimental pharmacology & physiology 47 (11) (2020)
Clemens Muehlan, Cedric Vaillant, Isabelle Zenklusen, Stephan Kraehenbuehl, Jasper Dingemanse
Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders. Expert opinion on drug metabolism & toxicology 16 (11) (2020)

Jasper Dingemanse.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Jasper Dingemanse